Tianci has no liabilities with respect to the payment of any taxes (including any deficiencies, interest or penalties), except for taxes accrued but not yet due and payable;

Irregularities in or deficiencies of title to any Property which do not materially affect the use of such property by [[Organization A:Organization]] or any of its Significant Subsidiaries in the normal course of its business.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

Total fees under this Agreement will not exceed $36,480 USD during the Term without Finch’s express written consent. Further, Finch will not reimburse Consultant for remediating obvious and avoidable deficiencies in any Services provided by Consultant.

QSHI will deliver to the Purchaser copies of all Tax Returns, examination reports, and statements of deficiencies assessed against, or agreed to by, QSHI for all Tax periods beginning after the date of QSHI’s incorporation, if any.

Except as set forth on [Schedule 5.15(e)], there are no outstanding requests, agreements, consents or waivers to extend the statutory period of limitations applicable to the assessment of any Taxes or deficiencies against any Subject Company.

Any deficiencies in the Collateral or any deficiency in the ability of Agent or any Lender to collect or to obtain performance from any Persons now or hereafter liable for the payment and performance of any obligation hereby guaranteed;

easements, rights-of-way, restrictions, encroachments and other similar charges or encumbrances, and minor title deficiencies, in each case not securing Indebtedness and that do not materially impair the conduct of the business of Borrower or any of its Subsidiaries;

All Products supplied to AYTU by TRIS under this Agreement will meet the Product Specifications as of the date that title to such Product is delivered to AYTU and TRIS shall continue to use Commercially Reasonable Efforts to rectify any deficiencies identified in the FDA Letter.

“Losses” shall mean all losses, damages, liabilities, deficiencies, Actions, judgments, interest, awards, penalties, fines, costs, or expenses of whatever kind, including reasonable attorneys’ fees and the cost of enforcing any right to indemnification hereunder and the cost of pursuing any insurance providers; provided, however, that “Losses” shall not include punitive damages, except to the extent actually awarded to a Governmental Authority or other third party.